Psoriasis

Stelara Approved to Treat Adolescent Patients With Plaque Psoriasis

By October 16, 2017

The expanded approval was supported by data from a Phase 3 study that evaluated the safety and efficacy of subcutaneous Stelara in adolescents aged ≥12 years.

Secukinumab Efficacy Evaluated in Patients with Scalp Psoriasis

September 29, 2017

Over half of patients have 90 percent improvement on Psoriasis Scalp Severity Index score

Tremfya Sustains Long-Term Skin Clearance in Plaque Psoriasis

By September 18, 2017

Patients who were crossed over to Tremfya from Humira showed substantial improvement in PSSD scores from Week 48 to Week 100.

Topical Coal Tar: An Effective Alternative for Psoriasis?

August 17, 2017

Coal tar is one of the oldest psoriasis treatments though its exact mechanism is not known.

Psoriatic Arthritis Treatment Trends Investigated

By August 15, 2017

Researchers used claims data between 2004-2015 from a large commercial database to identify patients with psoriatic arthritis who were initiated on DMARDs.

First Interchangeability Study Initiated for Adalimumab Biosimilar

By July 27, 2017

Researchers will compare the pharmacokinetics and clinical outcomes between patients continuously receiving Humira vs. repeatedly switching between Humira and BI 695501.

Biosimilar Renflexis Now Available

July 24, 2017

Infliximab products work by neutralizing the biological activity of TNF-alpha by binding with high affinity to the soluble and transmembrane forms of TNF-alpha and inhibiting the binding of TNF-alpha with its receptors.

Tremfya Approved for Moderate to Severe Plaque Psoriasis

By July 13, 2017

In the NAVIGATE study, 31% of patients treated with Tremfya were considered cleared or almost cleared vs. 14% of patients treated with Stelara (ustekinumab; Janssen Biotech) at Week 28.

FDA Clears At-Home Light Therapy Device for Psoriasis

By July 13, 2017

A clinical trial (Pfaff S et al. 2015) of 47 individuals with mild psoriasis found significant improvement in change from baseline of Local Psoriasis Severity Index in patients receiving UV-free blue light home treatment.

Tofacitinib Assessed for Efficacy in Nail Psoriasis

June 20, 2017

The researchers found that significantly more patients receiving tofacitinib 5mg and tofacitinib 10mg versus placebo achieved a ≥50% reduction in the Nail Psoriasis Severity Index (NAPSI) score from baseline (NAPSI50)

Ixekizumab Beneficial in Psoriatic Arthritis Refractory to TNFi

May 31, 2017

Two-week and four-week ixekizumab dosing regimens improved signs and symptoms

Tildrakizumab to Be Reviewed for Moderate-to-Severe Plaque Psoriasis

By May 24, 2017

Ongoing data from two Phase 3 trials, ReSurface 1 and ReSurface 2, which enrolled over 1,800 patients, is included in the BLA.

Xeljanz Under FDA Review for Psoriatic Arthritis

By May 05, 2017

An anticipated Prescription Drug User Fee Act (PDUFA) action date of December 2017 has been set by the FDA for both Xeljanz sNDAs.

Out-of-Pocket Spending for Topical Steroids Investigated

May 02, 2017

The researchers found that patients' out-of-pocket spending for topical steroids was $333.7 million. There was a 226.5% increase in total annual spending, from $237.6 million to $775.9 million.

Biosimilar Renflexis Gets FDA Approval

By April 21, 2017

A biosimilar product must demonstrate no clinically meaningful differences in safety or efficacy from the reference product.

Certain Factors May Influence Biologic Tx Choice in Psoriasis

April 13, 2017

The researchers found that the presence of psoriatic arthritis, weight, employment status, baseline disease severity all affect selection

PASI Scores Differ Between Sexes in Psoriasis

April 03, 2017

Women had significantly lower scores in all areas of the body than men, except for the head, in itemized PASI analyses.

Humira Label Updated With Fingernail Psoriasis Data

By March 30, 2017

The safety and efficacy of Humira in patients with moderate to severe fingernail psoriasis and moderate to severe chronic plaque psoriasis was evaluated in a Phase 3, multicenter, double-blind, randomized, parallel-arm, placebo-controlled study.

Psoriasis May Up Melanoma, Hematologic Cancer Risk

March 28, 2017

The researchers found that patients with psoriasis had 1.53 times greater risk of developing a malignancy versus patients without psoriasis (P<0.01).

Musculoskeletal Symptoms May Precede PsA Diagnosis

March 13, 2017

Prediction of subsequent PsA was associated with baseline presence of arthralgia in women (hazard ratio [HR], 2.59), heel pain (HR, 4.18), high fatigue score (HR, 2.36), and high stiffness score (HR, 2.03).

Study Investigates Transfer of TNFi Therapy to Breast Milk

By March 06, 2017

A study which assessed concentrations of certolizumab pegol (Cimzia; UCB) in human breast milk found that minimal to no transfer of drug from plasma to breast milk occurs.

Economic Impact of Skin Disease Highlighted in New Report

March 03, 2017

In the United States, dermatological conditions cost 75 billion in 2013, researchers say

Guselkumab Shows Superiority in Plaque Psoriasis Phase 3 Studies

By March 03, 2017

Janssen announced new findings from VOYAGE 2 and NAVIGATE, two pivotal Phase 3 studies evaluating guselkumab for the treatment of moderate to severe plaque psoriasis.

Psoriasis Treatment Linked to Drug-Induced Lupus Erythematosus

February 21, 2017

Patient with psoriasis developed muscle pain with paresthesia, ANA titer elevation with adalimumab

Ustekinumab Effective for Long-Term Remission in Crohn's Disease

By February 17, 2017

Among randomized patients who entered the long-term extension trial period , 79.2% of patients receiving ustekinumab every 12 weeks and 87.1% of patients receiving ustekinumab every 8 weeks were in remission,

FDA Approves Siliq for the Treatment of Plaque Psoriasis

By February 16, 2017

The drug carries a Black Box Warning and is available only through a restricted program.

Psoriasis Outcomes with Ixekizumab Impacted by Interrupted Therapy

By February 13, 2017

Psoriasis patients who interrupted therapy with ixekizumab displayed a reduced level of response.

Antifungal and Retinoid Combo Displays Anti-Aging Benefits

January 26, 2017

Climbazole enhances retinoid-associated biological activities in vivo and in vitro, according to a study published online January 19 in the International Journal of Cosmetic Science.

Perrigo Gets Approval for Generic Topicort Spray

January 24, 2017

Perrigo announced that the Food and Drug Administration (FDA) has approved the Abbreviated New Drug Application (ANDA) for Desoximetasone Topical Spray, 0.25%, the first generic of Taro's Topicort Spray, 0.25%.

Study Assesses QoL for Parents of Children With Psoriasis

January 23, 2017

Childhood psoriasis impacts parents' quality of life in multiple domains, especially their emotional well-being, according to a study published in the February issue of the Journal of the American Academy of Dermatology.